XBIO vs PRPO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 02, 2026

XBIO

41.3
AI Score
VS
PRPO Wins

PRPO

41.7
AI Score

Investment Advisor Scores

XBIO

41score
Recommendation
HOLD

PRPO

42score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric XBIO PRPO Winner
Revenue 6.71M 806,923 PRPO
Net Income -1.44M -456,382 XBIO
Net Margin -21.5% -56.6% PRPO
Operating Income -1.43M -502,117 XBIO
ROE -10.2% -6.6% XBIO
ROA -6.9% -5.8% XBIO
Total Assets 20.80M 7.91M PRPO
Cash 2.60M 7.35M XBIO
Current Ratio 1.56 7.93 XBIO

Relative Price Performance (Last 90 Days)

XBIO 1M: -4.0% · 3M: -10.4% PRPO 1M: -12.4% · 3M: -28.5%

Current Technical Phase

XBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 46

RSI (14): 46.0 · Price: $2.66

PRPO

Markdown
Sell / avoid

Price below a falling SMA50 (slope -8.1%), weak momentum, RSI 43

RSI (14): 42.9 · Price: $22.13

Fundamentals Snapshot

Metric XBIO PRPO
Market Cap
Forward P/E -7.8 15.4
Trailing P/E
Revenue (TTM)
Revenue Growth 0.4% 0.4%
Gross Margin 1.0% 0.4%
Operating Margin -0.6% -0.2%
EPS -1.19 -0.45
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, PRPO is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.